Format

Send to

Choose Destination
Oncotarget. 2016 Jan 19;7(3):2313-28. doi: 10.18632/oncotarget.6320.

Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?

Author information

1
Department of Radiation Oncology, University of Munich, Germany.
2
German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
3
Institute of Neurology (Edinger Institute), Goethe University, Frankfurt, Germany.
4
Department of Neuroradiology, University Hospital Bonn, Bonn, Germany.
5
Department of Neurology, University of Munich, Munich, Germany.
6
Department of Neurosurgery, University Hospital Regensburg, Regensburg, Germany.

Abstract

Glioblastoma (GBM) represents the most frequent primary brain tumor in adults and carries a dismal prognosis despite aggressive, multimodal treatment regimens involving maximal resection, radiochemotherapy, and maintenance chemotherapy. Histologically, GBMs are characterized by a high degree of VEGF-mediated vascular proliferation. In consequence, new targeted anti-angiogenic therapies, such as the monoclonal anti-VEGF-A antibody bevacizumab, have proven effective in attenuating tumor (neo)angiogenesis and were shown to possess therapeutic activity in several phase II trials. However, the role of bevacizumab in the context of multimodal therapy approaches appears to be rather complex. This review will give insights into current concepts, limitations, and controversies regarding the molecular mechanisms and the clinical benefits of bevacizumab treatment in combination with radio(chemo)therapy--particularly in face of the results of recent phase III trials, which failed to demonstrate convincing improvements in overall survival (OS).

KEYWORDS:

VEGF; angiogenesis; bevacizumab; glioma; radiotherapy

PMID:
26575171
PMCID:
PMC4823037
DOI:
10.18632/oncotarget.6320
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center